Omnicef (cefdinir) / Abbott - LARVOL DELTA

Rare Presentation of Warm Autoimmune Hemolytic Anemia Secondary to Ulcerative Colitis Flare (ACG 2026) - "Case Description/ A 30-year-old female with a history of recent URI treated with cefdinir, UC well-controlled on maintenance vedolizumab, with prior failure of mesalamine, budesonide, and adalimumab, presented with fatigue and 5-6 episodes of hematochezia daily for one week...She was evaluated by Hematology with concern for WAHA in the setting of UC flare, and initiated on high dose corticosteroids followed by weekly rituximab...Our case highlights the importance of an accurate timeline of symptoms and quickly identifying potential inciting illness or medications to guide efficient diagnostic evaluation/treatment, particularly in the setting of rare presentations. Figure: Low Power View of Acute Inflammation within the Colonic Epithelium Figure: Surface Erosion as Evidenced by Sloughing of the Surface Epithelium"

Anemia • Autoimmune Hemolytic Anemia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Musculoskeletal Diseases • Ulcerative Colitis • HP • IL23A

Elevated Procalcitonin and Acute Hepatitis in Cefdinir-Induced DRESS Syndrome Masquerading as Sepsis (ACG 2026) - "Cefdinir was discontinued and intravenous methylprednisolone was initiated with rapid clinical improvement. The combination of eosinophilia, acute hepatitis with hepatomegaly, myositis with weakness, serosal involvement, recent antibiotic exposure, and rapid corticosteroid response supported the diagnosis. Early recognition, discontinuation of the offending agent, and corticosteroid therapy are critical for recovery."

Cardiovascular • Cognitive Disorders • Eosinophilia • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure • Myositis • Nephrology • Septic Shock

Efficacy of Oral Step-Down Therapy with Amoxicillin-Clavulanate Alone or in Combination with Cefdinir for ESBL-Producing Complicated Urinary Tract Infections: A Retrospective Study (IDWeek 2026) - No abstract available

Combination therapy • Retrospective data • Infectious Disease

Outcomes of Cefdinir Compared to Alternative Antibiotics for the Treatment of Urinary Tract Infections (IDWeek 2026) - No abstract available

Infectious Disease

Cefpodoxime versus Cefdinir for Treatment of Urinary Tract Infections in Emergency Department Patients (IDWeek 2026) - No abstract available

Clinical • Infectious Disease

Cefdinir in the Crosshairs: An Antimicrobial Stewardship Strategy to Curb Inappropriate Use (IDWeek 2026) - No abstract available

Infectious Disease

POPS or POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (clinicaltrials.gov) - P=N/A | N=5000 | Recruiting | Sponsor: Duke University | Trial completion date: Jul 2027 ➔ Dec 2026 | Trial primary completion date: Mar 2027 ➔ Nov 2026

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Asthma • Attention Deficit Hyperactivity Disorder • Bronchopulmonary Dysplasia • Cardiovascular • CNS Disorders • Dermatology • Developmental Disorders • Endocrine Disorders • Genetic Disorders • Gynecology • Heart Failure • Hematological Disorders • Hemophilia • Hypertension • Immunology • Infectious Disease • Insomnia • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Pain • Pneumonia • Psychiatry • Pulmonary Arterial Hypertension • Pulmonary Disease • Rare Diseases • Renal Disease • Respiratory Diseases • Sleep Disorder

Impact of a Formulary Change and Implementation of a Legacy Medication Alternative in the Electronic Medical Record on Antibiotic Prescribing In Children. (PubMed, J Pediatr Pharmacol Ther) - "After the formulary changes involving cefdinir, there was no significant decrease in cefdinir use or in optimal de-escalation rates. There were significantly lower hospital re-encounters and shorter lengths of stay, though further studies are needed to validate these findings."

Journal • Infectious Disease • Nephrology • Pediatrics • Pneumonia • Respiratory Diseases

Evaluation of the Appropriateness of Pediatric Cefdinir Prescribing. (PubMed, Clin Pediatr (Phila)) - "Non-pediatric-trained providers were responsible for 46.8% of the potentially inappropriate cefdinir prescriptions and were more likely to prescribe potentially inappropriate cefdinir prescriptions compared with pediatric-trained providers (P < .001). Advanced practice providers were more likely than physician providers to prescribe potentially inappropriate cefdinir prescriptions (P < .001)."

Journal • Infectious Disease • Nephrology • Otorhinolaryngology • Pediatrics • Pneumonia • Respiratory Diseases • Sinusitis

Comparison of oral third- versus first-/ second-generation cephalosporins for acute uncomplicated cystitis: a nationwide retrospective cohort study. (PubMed, Eur J Clin Microbiol Infect Dis) - "Oral third-generation cephalosporins may be associated with more frequent additional antibiotic treatment compared with cephalexin or cefaclor in the management of uncomplicated cystitis."

Journal • Retrospective data • Infectious Disease • Nephrology

Case Report: Congenital chloride diarrhea in a prepubertal girl with perianal fistula and colonic ulcers. (PubMed, Front Pediatr) - "While the colonic ulcerations resolved under standard conservative medical treatment, the concurrent perianal fistula completely healed using an innovative, non-surgical approach consisting of local rectal antibiotic application (cefdinir powder) and antiseptic sitz baths. This case demonstrates that CCD can present with unusual structural complications. Crucially, although CCD typically manifests in early infancy, clinicians should consider this genetic metabolic disorder even in older children presenting with chronic diarrhea and recurrent electrolyte disturbances."

Journal • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Nephrology

Regulation of PBP2x Surface Localization by aliD and clpL Alters β-Lactam Resistance in Pneumococcus. (PubMed, Pathogens) - "aliD-expressing strains exhibit elevated minimum inhibitory concentrations (MICs) to the β-lactam antibiotics amoxicillin and cefdinir compared to isogenic aliD mutants. In contrast, aliD had minimal effects on susceptibility to vancomycin, suggesting a mechanism specific to β-lactam antibiotics...Together, these findings identify a novel regulatory pathway in which aliD enhances clpL expression, promotes PBP2x surface exposure, and increases peptidoglycan cross-linking, ultimately reducing β-lactam susceptibility. This work expands current understanding of pneumococcal antibiotic resistance and suggests that peptide sensing through oligopeptide transport systems may influence antibiotic susceptibility in host-specific environments."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Microwave-assisted eco-friendly synthesis of carbon quantum dots derived Cichorium intybus for fluorometric detection of cefdinir. (PubMed, Sci Rep) - "This work broadens the use of CQDs in pharmaceutical analysis, spiked plasma and synthetic urine samples. CACI tool guaranteed that upcoming analytical techniques using the CQDs fluorescence probe satisfy the changing needs of both industrial applications and scientific research."

Journal

Efficacy and safety of 24 antibiotics for group A streptococcal pharyngitis: a network meta-analysis of 64 randomized controlled trials. (PubMed, Front Public Health) - "For late bacterial eradication, cefprozil demonstrated greater efficacy compared with penicillin V (OR: 3.12; 95% CI: 1.03-11.25), whereas azithromycin exhibited suboptimal performance (OR: 0.38; 95% CI: 0.25-0.62). For early clinical response, cefdinir (OR: 2.01; 95% CI: 1.28-3.25) and cefuroxime axetil (OR: 2.14; 95% CI: 1.19-3.60) demonstrated significantly greater efficacy compared with penicillin V. For late clinical response, spiramycin showed superior efficacy to penicillin V (OR: 0.17; 95% CI: 0.02-0.94), although evidence was limited to a single small trial...Conversely, azithromycin should be avoided due to inferior efficacy and increased adverse risks. http://www.crd.york.ac.uk/prospero, identifier CRD420251104703."

Clinical • Journal • Retrospective data • Review

Cefdinir reprograms Gram-positive bacteria to synergize with lysozyme against superbugs. (PubMed, mLife) - "Antibacterial efficacy of combination therapy is validated in both cell-based infection models and rat skin infection models, demonstrating strong translational potential. Given the established safety profiles of both agents, this sensitization strategy can be applied to human clinical research to combat MDR Gram-positive bacterial infections."

Journal • Dermatology • Infectious Disease

Provider report cards as a scalable tool for outpatient antibiotic stewardship: insights from a medicaid claims-based approach. (PubMed, Antimicrob Steward Healthc Epidemiol) - "We evaluated Medicaid claims-based provider report cards as a scalable stewardship tool. Quarterly audit and feedback improved guideline concordance, diagnostic appropriateness, and reduced cefdinir use; highlighting claims-based electronic feedback as a sustainable outpatient antimicrobial stewardship strategy suitable for statewide implementation."

Journal • Reimbursement • US reimbursement • Pediatrics

Cefdinir-Ornidazole for Bowel Preparation Before Colorectal Surgery: A Retrospective Cohort Study. (PubMed, J Surg Res) - "MBP combined with oral cefdinir and ornidazole before colorectal surgery is associated with significantly lower SSI rates. However, it remains imperative that large-scale prospective studies be conducted to validate its safety profile."

Journal • Retrospective data • Review • Infectious Disease

Fever of Unknown Origin: A Diagnostic Challenge with Current Lipid Lowering Therapies (ENDO 2026) - "At discharge, evolocumab 140 mg every two weeks subcutaneously and ezetimibe 10mg daily were added to atorvastatin 80 mg daily...She received two courses of cefdinir, in October 2024 and January 2025, without resolution of fevers...Given the long half-life of evolocumab (11-17 days), and lack of correlation in timing of fever episodes with evolocumab dosing, the association may be hard to identify as symptoms can persist even after not taking medication for >1 month. High degree of suspicion is needed to arrive to this diagnosis."

Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Metabolic Disorders • Musculoskeletal Pain • Otorhinolaryngology • Type 2 Diabetes Mellitus

TUBERCULOUS PAROTITIS MIMICKING A BRANCHIAL CLEFT ANOMALY IN A CHILD (ESPID 2026) - "His symptoms had resolved following amoxicillin–clavulanate and clindamycin one month earlier; however, the same complaints recurred...Due to recurrence despite antibiotic therapy, the patient was admitted and treated with ceftriaxone and clindamycin...Despite clindamycin and cefdinir therapy, ultrasonography continued to show a branchial cleft sinus tract...Therapy was continued with isoniazid and rifampicin for a total of six months, without drug- related complications. Learning Points/Discussion This case highlights the diagnostic challenges of tuberculous parotitis in children and underscores the limitations of clinical and microbiological evaluation in such rare presentations."

Clinical • Infectious Disease • Mumps • Tuberculosis

Cefdinir binding to a class A β-lactamase revealed by serial cryo-crystallography. (PubMed, Acta Crystallogr D Struct Biol) - "Cefdinir is an extended-spectrum third-generation cephalosporin administered since the late 1990s; despite this, there is no reported 3D structure of the antibiotic bound to any β-lactamase or penicillin-binding protein in the PDB. Here, we report the X-ray crystallographic structure of cefdinir-bound CTX-M-14 E166A mutant obtained via serial cryo-crystallography."

Journal • Infectious Disease

POPS or POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (clinicaltrials.gov) - P=N/A | N=5000 | Recruiting | Sponsor: Duke University | Trial primary completion date: Sep 2026 ➔ Mar 2027

Trial primary completion date • ADHD (Impulsive Aggression) • Asthma • Attention Deficit Hyperactivity Disorder • Bronchopulmonary Dysplasia • Cardiovascular • CNS Disorders • Dermatology • Developmental Disorders • Endocrine Disorders • Genetic Disorders • Gynecology • Heart Failure • Hematological Disorders • Hemophilia • Hypertension • Immunology • Infectious Disease • Insomnia • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Pain • Pneumonia • Psychiatry • Pulmonary Arterial Hypertension • Pulmonary Disease • Rare Diseases • Renal Disease • Respiratory Diseases • Sleep Disorder

Novel naphthalimide-derived cephalosporins as potential multitargeting anti-MRSA candidates. (PubMed, Bioorg Chem) - "Some prepared NCs exhibited potent antibacterial activities, aminothiazolyl oxime NC 47 (MIC = 0.5 μg/mL) showed 16-fold and 4-fold greater potency against MRSA than clinical norfloxacin and cefdinir, respectively. Moreover, NC 47 could also bind to the allosteric site of PBP2a, thereby inducing the opening of active site and overcoming classical β-lactam resistance. This series of results implied the large potential of naphthalimide-derived cephalosporins as multitargeting anti-MRSA candidates to combat bacterial infection."

Journal • Hematological Disorders • Infectious Disease

Effectiveness of 5- Versus 7-Day Antibiotic Courses for Acute Otitis Media in Children Aged 2-5 Years: A Multicenter Retrospective Cohort Study (PAS 2026) - "Among 6,389 children (median age 3 years; 55% male), amoxicillin was prescribed in 89.5% and cefdinir in 10.5%. Duration distribution was 5 days (14.6%), 6-7 days (24%), and >7 days (61.4%). Overall treatment failure was uncommon (1.4%)."

Retrospective data • Infectious Disease • Otorhinolaryngology

A Rare Case of Stevens-Johnson Syndrome in a Young Patient Presenting With Odynophagia Following Antibiotic Use. (PubMed, Am J Case Rep) - "Initial management included cessation of cefdinir, intravenous fluids, corticosteroids, and broad supportive care...He was treated with intravenous immunoglobin and azithromycin, with gradual improvement and full recovery after a 2-week hospital course...Clinicians should maintain a high index of suspicion for SJS in patients presenting with acute mucositis and odynophagia following recent medication use or respiratory illness, even when the cutaneous findings are absent. Early identification, withdrawal of the offending agent, and prompt multidisciplinary care are critical to favorable outcomes."

Journal • Conjunctivitis • Infectious Disease • Mucositis • Ocular Infections • Ocular Inflammation • Ophthalmology • Otorhinolaryngology • Pneumonia • Respiratory Diseases • Steven-Johnson Syndrome

Computational Prediction and In Vitro Validation of Potential Molecular Targets Associated with Adverse Reactions of Antimicrobial Drugs in Neonates. (PubMed, Assay Drug Dev Technol) - "We initially identified adverse reactions associated with commonly used antimicrobial drugs such as Ceftazidime, Meropenem, Levofloxacin, Cefdinir, and Avibactam through DrugBank. The findings suggest that these drugs may cause adverse reactions by affecting the function of specific off-target proteins. This discovery provides valuable molecular insights into the mechanisms of adverse reactions and establishes a scientific basis for the rational design of safer drug analogs and for informing future antimicrobial treatment research for neonates."

Journal • Preclinical • Allergy • Gastrointestinal Disorder • Liver Failure • Nephrology • Renal Disease • AKR1B1